These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 33471679)
1. Differential Endocrine and Metabolic Effects of Testosterone Suppressive Agents in Transgender Women. Sofer Y; Yaish I; Yaron M; Bach MY; Stern N; Greenman Y Endocr Pract; 2020 Aug; 26(8):883-890. PubMed ID: 33471679 [TBL] [Abstract][Full Text] [Related]
2. Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women. Fung R; Hellstern-Layefsky M; Tastenhoye C; Lega I; Steele L J Sex Med; 2016 Nov; 13(11):1765-1772. PubMed ID: 27693265 [TBL] [Abstract][Full Text] [Related]
3. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial. Burinkul S; Panyakhamlerd K; Suwan A; Tuntiviriyapun P; Wainipitapong S J Sex Med; 2021 Jul; 18(7):1299-1307. PubMed ID: 34274044 [TBL] [Abstract][Full Text] [Related]
4. Low-Dose Cyproterone Acetate Treatment for Transgender Women. Even Zohar N; Sofer Y; Yaish I; Serebro M; Tordjman K; Greenman Y J Sex Med; 2021 Jul; 18(7):1292-1298. PubMed ID: 34176757 [TBL] [Abstract][Full Text] [Related]
5. Low estrogen doses normalize testosterone and estradiol levels to the female range in transgender women. Cunha FS; Domenice S; Sircili MHP; Mendonca BB; Costa EMF Clinics (Sao Paulo); 2018; 73():e86. PubMed ID: 29723345 [TBL] [Abstract][Full Text] [Related]
6. TESTOSTERONE LEVELS ACHIEVED BY MEDICALLY TREATED TRANSGENDER WOMEN IN A UNITED STATES ENDOCRINOLOGY CLINIC COHORT. Liang JJ; Jolly D; Chan KJ; Safer JD Endocr Pract; 2018 Feb; 24(2):135-142. PubMed ID: 29144822 [TBL] [Abstract][Full Text] [Related]
7. PROLACTIN LEVELS DO NOT RISE AMONG TRANSGENDER WOMEN TREATED WITH ESTRADIOL AND SPIRONOLACTONE. Bisson JR; Chan KJ; Safer JD Endocr Pract; 2018 Jul; 24(7):646-651. PubMed ID: 29708436 [TBL] [Abstract][Full Text] [Related]
8. Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men. Moltz L; Römmler A; Post K; Schwartz U; Hammerstein J Contraception; 1980 Apr; 21(4):393-413. PubMed ID: 6771095 [TBL] [Abstract][Full Text] [Related]
9. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Erenus M; Yücelten D; Gürbüz O; Durmuşoğlu F; Pekin S Fertil Steril; 1996 Aug; 66(2):216-9. PubMed ID: 8690104 [TBL] [Abstract][Full Text] [Related]
10. Use of low-dosage oral cyproterone acetate as a male contraceptive. Wang C; Yeung KK Contraception; 1980 Mar; 21(3):245-72. PubMed ID: 6771091 [TBL] [Abstract][Full Text] [Related]
11. Low dose of cyproterone acetate and testosterone enanthate for contraception in men. Meriggiola MC; Bremner WJ; Costantino A; Di Cintio G; Flamigni C Hum Reprod; 1998 May; 13(5):1225-9. PubMed ID: 9647551 [TBL] [Abstract][Full Text] [Related]
12. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. Meriggiola MC; Bremner WJ; Paulsen CA; Valdiserri A; Incorvaia L; Motta R; Pavani A; Capelli M; Flamigni C J Clin Endocrinol Metab; 1996 Aug; 81(8):3018-23. PubMed ID: 8768868 [TBL] [Abstract][Full Text] [Related]
13. Spironolactone as a single agent for long-term therapy of hirsute patients. Spritzer PM; Lisboa KO; Mattiello S; Lhullier F Clin Endocrinol (Oxf); 2000 May; 52(5):587-94. PubMed ID: 10792338 [TBL] [Abstract][Full Text] [Related]
14. A comparison of 5-year administration of cyproterone acetate or leuprolide acetate in combination with estradiol in transwomen. Gava G; Mancini I; Alvisi S; Seracchioli R; Meriggiola MC Eur J Endocrinol; 2020 Dec; 183(6):561-569. PubMed ID: 33055297 [TBL] [Abstract][Full Text] [Related]
15. Changes in Serum Testosterone and Adrenal Androgen Levels in Transgender Women With and Without Gonadectomy. Collet S; Gieles NC; Wiepjes CM; Heijboer AC; Reyns T; Fiers T; Lapauw B; den Heijer M; T'Sjoen G J Clin Endocrinol Metab; 2023 Jan; 108(2):331-338. PubMed ID: 36201493 [TBL] [Abstract][Full Text] [Related]
16. The efficacy of and user satisfaction with different antiandrogens in Chinese transgender women. Yang W; Hong T; Chang X; Han M; Gao H; Pan B; Zhao Z; Liu Y Int J Transgend Health; 2024; 25(3):471-482. PubMed ID: 39055628 [TBL] [Abstract][Full Text] [Related]
17. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113 [TBL] [Abstract][Full Text] [Related]
18. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations. Wallace EM; Gow SM; Wu FC J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955 [TBL] [Abstract][Full Text] [Related]
19. Effects of cross-sex hormone treatment on transgender women and men. Deutsch MB; Bhakri V; Kubicek K Obstet Gynecol; 2015 Mar; 125(3):605-610. PubMed ID: 25730222 [TBL] [Abstract][Full Text] [Related]
20. Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness. Gava G; Cerpolini S; Martelli V; Battista G; Seracchioli R; Meriggiola MC Clin Endocrinol (Oxf); 2016 Aug; 85(2):239-46. PubMed ID: 26932202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]